INS and Insulin resistance: Benefits were also observed for homeostatic model assessment of insulin resistance (HOMA-IR: MD -1.14, 95% CI [-1.35, -0.94], <i>P</i> < 0.00001), fasting insulin (FI: MD -23.40 pmol/L, 95% CI [-32.80, -14.01], <i>P</i> < 0.00001), triglycerides, and reproductive outcomes (live births: Risk Ratio [RR] 2.29, 95% CI [1.07, 4.93], <i>P</i> = 0.03; ovulation rate: RR 2.75, 95% CI [1.71, 4.41], <i>P</i> < 0.0001).